Remdesivir treatment for patients with moderate to severe COVID-19

Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 880 - 887 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5387 İndeks Tarihi: 14-12-2022

Remdesivir treatment for patients with moderate to severe COVID-19

Öz:
Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF <30 mL/min or dialysis and receiving favipiravir were the exclusion criteria of the study. Results: Among 500 patients, 494 patients were included in the study. On admission, 392 (79.3%) patients had moderate and 102 (20.6%) patients had severe COVID-19. The 28-day mortality was 10.1%. The median of the scores of the seven-category ordinal scale assessed on days 0, 3, 5, 7 were 4 and 3 on day 14. When the survival status of the patients was evaluated according to the time between the remdesivir start date and the end date of the symptoms, no statistically significant difference was found between the medians of the groups (p = 0.404). In multivariable analysis, age (OR, 1.05; 95%CI, 1.02–1.08; p = 0.003), $SpO_2$ level on admission (OR, 3.03; 95%CI, 1.35–6.81; p = 0.007), heart rate (OR, 2.48; 95%CI, 1.01–6.07; p = 0.047), follow-up site at the hospital (clinic/ICU) (OR, 26.4; 95%CI, 11.6–60.17; p < 0.001) were independently associated with increased mortality. Grade 3 adverse event (AE) was observed in 4 (0.8%) patients. None of the patients experienced grade 4 or 5 AEs. Conclusion: Remdesivir is a safe and well-tolerated drug and older age, low SpO2 level on admission, tachycardia, and ICU admission are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.
Anahtar Kelime: COVID-19 remdesivir antiviral treatment mortality

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine 2017; 9: 396. doi.org/10.1126/scitranslmed.aal3653
  • 2. Wang M, Cao R, Zhang L, Yang X, Liu J et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020; 30: 269–71. doi.org/10.1038/s41422-020-0282-0
  • 3. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine 2020; 383 (19): 1813-1826. doi.org/10.1056/NEJMoa2007764
  • 4. Wang Y, Fan G, Horby P, Hayden F, Li Q et al. Comparative Outcomes of Adults Hospitalized with Seasonal Influenza A or B Virus Infection: Application of the 7-Category Ordinal Scale. Open Forum Infectious Disease 2019; 6 (3): ofz053. doi: 10.1093/ofid/ofz053
  • 5. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao- Restrepo AM, Preziosi MP, Sathiyamoorthy V et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. New England Journal of Medicine 2021; 384 (6): 497- 511. doi: 10.1056/NEJMoa2023184
  • 6. Wang Y, Zhang D, Du G, Du R, Zhao J et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo- controlled, multicentre trial. Lancet. 2020; 395 (10236): 1569- 1578. doi: 10.1016/S0140-6736(20)31022-9
  • 7. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine 2020; 382: 2327–36. doi.org/10.1056/NEJMoa2007016
  • 8. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infectious Disease 2022; 22 (2): 209-221. doi: 10.1016/S1473-3099(21)00485-0
  • 9. Kaka AS, MacDonald R, Greer N, Vela K, Duan-Porter W et al. Major Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Annals of Internal Medicine 2021; 174 (5): 663-672. doi: 10.7326/M20-8148
  • 10. Enoki Y, Igarashi Y, Watabe Y, Honma K, Suzuki Y et al. Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials. Journal of Global Antimicrobial Resistance 2021; 24: 81–2. doi.org/10.1016/j.jgar.2020.11.022
  • 11. Kow CS, Aldeyab M, Hasan SS. Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials. Journal of Medical Virology 2021; 93: 1860–1. doi.org/10.1002/jmv.26638
  • 12. Piscoya A, Ng-Sueng LF, Parra Del Riego A, Cerna-Viacava R, Pasupuleti V et al. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta- analysis. PLoS One. 2020; 15 (12): e0243705. doi: 10.1371/ journal.pone.0243705
  • 13. Shrestha DB, Budhathoki P, Syed N-I-H, Rawal E, Raut S et al. Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis. Life Sciences 2021; 264: 118663. doi.org/10.1016/j.lfs.2020.118663
  • 14. Tasavon Gholamhoseini M, Yazdi-Feyzabadi V, Goudarzi R, Mehrolhassani MH. Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta- Analysis. Journal of Pharmacy and Pharmaceutical Sciences 2021; 24: 237-245. doi: 10.18433/jpps31870
  • 15. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PloS One 2021; 16: e0248132. doi.org/10.1371/journal.pone.0248132
  • 16. Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacological Research 2020; 158: 104899. doi.org/10.1016/j.phrs.2020.104899
  • 17. Katzenschlager S, Zimmer AJ, Gottschalk C, Grafeneder J, Schmitz S et al. Can we predict the severe course of COVID-19 - a systematic review and meta-analysis of indicators of clinical outcome? PloS One 2021; 16: e0255154. doi.org/10.1371/ journal.pone.0255154
  • 18. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infectious Diseases 2021; 21: 855. doi.org/10.1186/s12879-021-06536-3
  • 19. Demir Önder K, Seremet Keskin A, Berk H, Seyman D, Öztoprak N. Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients. Turkish Journal of Medical Sciences 2021; 51: 2835–49. doi. org/10.3906/sag-2106-114
  • 20. Flisiak R, Zarębska-Michaluk D, Berkan-Kawińska A, Tudrujek- Zdunek M, Rogalska M et al. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Polish Archives of Internal Medicine 2021; 131 (1): 103-110. doi: 10.20452/ pamw.15735
  • 21. Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G et al. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clinical Translational Science 2020; 13: 896–906. doi.org/10.1111/ cts.12840
  • 22. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine 2020; 383: 1827–37. doi. org/10.1056/NEJMoa2015301
APA Hasanoglu I, GÜNER R, Çelik İ, KANAT F, Batirel A, Dizman G, Eryilmaz-Eren E, Yildiz Sevgi D, bozkurt i, Kart Yaşar K, Şenoğlu S, Kazak E, KARAALİ R, kocagül çelikbaş a, Pullukçu H, ÇAGATAY A, Unal S, ERDINC F, Tabak F, Gül A, Alp E (2022). Remdesivir treatment for patients with moderate to severe COVID-19. , 880 - 887. 10.55730/1300-0144.5387
Chicago Hasanoglu Imran,GÜNER RAHMET,Çelik İlhami,KANAT FIKRET,Batirel Ayse,Dizman Gülçin Telli,Eryilmaz-Eren Esma,Yildiz Sevgi Dilek,bozkurt ilkay,Kart Yaşar Kadriye,Şenoğlu Sevtap,Kazak Esra,KARAALİ Rıdvan,kocagül çelikbaş aysel,Pullukçu Hüsnü,ÇAGATAY ARIF ATAHAN,Unal Serhat,ERDINC Fatma Sebnem,Tabak Fehmi,Gül Ahmet,Alp Emine Remdesivir treatment for patients with moderate to severe COVID-19. (2022): 880 - 887. 10.55730/1300-0144.5387
MLA Hasanoglu Imran,GÜNER RAHMET,Çelik İlhami,KANAT FIKRET,Batirel Ayse,Dizman Gülçin Telli,Eryilmaz-Eren Esma,Yildiz Sevgi Dilek,bozkurt ilkay,Kart Yaşar Kadriye,Şenoğlu Sevtap,Kazak Esra,KARAALİ Rıdvan,kocagül çelikbaş aysel,Pullukçu Hüsnü,ÇAGATAY ARIF ATAHAN,Unal Serhat,ERDINC Fatma Sebnem,Tabak Fehmi,Gül Ahmet,Alp Emine Remdesivir treatment for patients with moderate to severe COVID-19. , 2022, ss.880 - 887. 10.55730/1300-0144.5387
AMA Hasanoglu I,GÜNER R,Çelik İ,KANAT F,Batirel A,Dizman G,Eryilmaz-Eren E,Yildiz Sevgi D,bozkurt i,Kart Yaşar K,Şenoğlu S,Kazak E,KARAALİ R,kocagül çelikbaş a,Pullukçu H,ÇAGATAY A,Unal S,ERDINC F,Tabak F,Gül A,Alp E Remdesivir treatment for patients with moderate to severe COVID-19. . 2022; 880 - 887. 10.55730/1300-0144.5387
Vancouver Hasanoglu I,GÜNER R,Çelik İ,KANAT F,Batirel A,Dizman G,Eryilmaz-Eren E,Yildiz Sevgi D,bozkurt i,Kart Yaşar K,Şenoğlu S,Kazak E,KARAALİ R,kocagül çelikbaş a,Pullukçu H,ÇAGATAY A,Unal S,ERDINC F,Tabak F,Gül A,Alp E Remdesivir treatment for patients with moderate to severe COVID-19. . 2022; 880 - 887. 10.55730/1300-0144.5387
IEEE Hasanoglu I,GÜNER R,Çelik İ,KANAT F,Batirel A,Dizman G,Eryilmaz-Eren E,Yildiz Sevgi D,bozkurt i,Kart Yaşar K,Şenoğlu S,Kazak E,KARAALİ R,kocagül çelikbaş a,Pullukçu H,ÇAGATAY A,Unal S,ERDINC F,Tabak F,Gül A,Alp E "Remdesivir treatment for patients with moderate to severe COVID-19." , ss.880 - 887, 2022. 10.55730/1300-0144.5387
ISNAD Hasanoglu, Imran vd. "Remdesivir treatment for patients with moderate to severe COVID-19". (2022), 880-887. https://doi.org/10.55730/1300-0144.5387
APA Hasanoglu I, GÜNER R, Çelik İ, KANAT F, Batirel A, Dizman G, Eryilmaz-Eren E, Yildiz Sevgi D, bozkurt i, Kart Yaşar K, Şenoğlu S, Kazak E, KARAALİ R, kocagül çelikbaş a, Pullukçu H, ÇAGATAY A, Unal S, ERDINC F, Tabak F, Gül A, Alp E (2022). Remdesivir treatment for patients with moderate to severe COVID-19. Turkish Journal of Medical Sciences, 52(4), 880 - 887. 10.55730/1300-0144.5387
Chicago Hasanoglu Imran,GÜNER RAHMET,Çelik İlhami,KANAT FIKRET,Batirel Ayse,Dizman Gülçin Telli,Eryilmaz-Eren Esma,Yildiz Sevgi Dilek,bozkurt ilkay,Kart Yaşar Kadriye,Şenoğlu Sevtap,Kazak Esra,KARAALİ Rıdvan,kocagül çelikbaş aysel,Pullukçu Hüsnü,ÇAGATAY ARIF ATAHAN,Unal Serhat,ERDINC Fatma Sebnem,Tabak Fehmi,Gül Ahmet,Alp Emine Remdesivir treatment for patients with moderate to severe COVID-19. Turkish Journal of Medical Sciences 52, no.4 (2022): 880 - 887. 10.55730/1300-0144.5387
MLA Hasanoglu Imran,GÜNER RAHMET,Çelik İlhami,KANAT FIKRET,Batirel Ayse,Dizman Gülçin Telli,Eryilmaz-Eren Esma,Yildiz Sevgi Dilek,bozkurt ilkay,Kart Yaşar Kadriye,Şenoğlu Sevtap,Kazak Esra,KARAALİ Rıdvan,kocagül çelikbaş aysel,Pullukçu Hüsnü,ÇAGATAY ARIF ATAHAN,Unal Serhat,ERDINC Fatma Sebnem,Tabak Fehmi,Gül Ahmet,Alp Emine Remdesivir treatment for patients with moderate to severe COVID-19. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.880 - 887. 10.55730/1300-0144.5387
AMA Hasanoglu I,GÜNER R,Çelik İ,KANAT F,Batirel A,Dizman G,Eryilmaz-Eren E,Yildiz Sevgi D,bozkurt i,Kart Yaşar K,Şenoğlu S,Kazak E,KARAALİ R,kocagül çelikbaş a,Pullukçu H,ÇAGATAY A,Unal S,ERDINC F,Tabak F,Gül A,Alp E Remdesivir treatment for patients with moderate to severe COVID-19. Turkish Journal of Medical Sciences. 2022; 52(4): 880 - 887. 10.55730/1300-0144.5387
Vancouver Hasanoglu I,GÜNER R,Çelik İ,KANAT F,Batirel A,Dizman G,Eryilmaz-Eren E,Yildiz Sevgi D,bozkurt i,Kart Yaşar K,Şenoğlu S,Kazak E,KARAALİ R,kocagül çelikbaş a,Pullukçu H,ÇAGATAY A,Unal S,ERDINC F,Tabak F,Gül A,Alp E Remdesivir treatment for patients with moderate to severe COVID-19. Turkish Journal of Medical Sciences. 2022; 52(4): 880 - 887. 10.55730/1300-0144.5387
IEEE Hasanoglu I,GÜNER R,Çelik İ,KANAT F,Batirel A,Dizman G,Eryilmaz-Eren E,Yildiz Sevgi D,bozkurt i,Kart Yaşar K,Şenoğlu S,Kazak E,KARAALİ R,kocagül çelikbaş a,Pullukçu H,ÇAGATAY A,Unal S,ERDINC F,Tabak F,Gül A,Alp E "Remdesivir treatment for patients with moderate to severe COVID-19." Turkish Journal of Medical Sciences, 52, ss.880 - 887, 2022. 10.55730/1300-0144.5387
ISNAD Hasanoglu, Imran vd. "Remdesivir treatment for patients with moderate to severe COVID-19". Turkish Journal of Medical Sciences 52/4 (2022), 880-887. https://doi.org/10.55730/1300-0144.5387